The oxytocin antagonist [Mpa1, 
Introduction
In pregnant females at term, oxytocin signalling in the uterus is upregulated. The increase in oxytocin-mediated events is believed to be responsible for the onset of coordinated and forceful contractions that lead to the expulsion of the concep¬ tus. However, the molecular mechanisms underlying oxytocininduced uterine hyperactivity are still unclear. An increase in the circulating concentration of oxytocin, uterine responsive¬ ness to oxytocin (Fuchs and Fuchs, 1984; Casey and MacDonald, 1988;  Leake, 1990; Steer, 1990) and the synthesis of oxytocin in the uterus (Ciarochi et ah, 1985; Lefebvre et ah, 1992) have been suggested to be involved.
In any case, the activation of the uterine oxytocin receptor is an obligate step for oxytocin-induced activation of cells in the uterus. Hence, the more rational approach to treating premature labour is the downregulation or blockade of the oxytocin receptor. From animal studies, the only factor known to downregulate the uterine expression of the oxyto¬ cin receptor is progesterone (Soloff, 1975; Nissenson et ah, 1978; Hixon and Flint, 1987) . However, this steroid has been shown to be ineffective in preventing premature labour in humans (Fuchs and Stakemann, 1960) . Furthermore, progesterone apparently does not inhibit the expression of the oxytocin receptor in humans (Maggi et ah, 1992) . Recent studies have, therefore, focused on the development of oxytocin receptor antagonists, a whole series of which have been synthesized during the past 20 years (Sawyer and Manning, 1989) .
One of these antagonists, [MpaI,D-Tyr(Et) (Akerlund et ah, 1987; Andersen el ah, 1987) ; this antagonist inhibited uterine contrac¬ tions in all (Akerlund et ah, 1987) or in the majority (Andersen et ah, 1987) of the patients studied. Although dETVT binds with high affinity (Fuchs et ah, 1987) and selectivity (Pettibone et ah, 1992) to the oxytocin receptor in the rodent uterus, it has 10 times less affinity for the oxytocin receptor than has oxy¬ tocin in the human myometrium (Fuchs et ah, 1987) . Further¬ more, in the human uterus and liver, dETVT binds with high affinity to the VI vasopressin receptor (Pettibone et ah, 1992) .
Since both oxytocin receptors and VI vasopressin receptors are present in the rabbit (Maggi ei ah, 1988b (Maggi ei ah, , 1991a and human (Maggi et ah, 1990 (Maggi et ah, , 1992 (Maggi et ah, 1992) [patient 1 (Ml) Myometrial cells were prepared as previously described (Maggi et ah, 1991b 
Analysis of experimental results
The binding data were evaluated quantitatively with non¬ linear least squares curve fitting using the computer program LIGAND (Munson and Rodbard, 1980 (Munson and Rodbard, 1980 (1988b, 1990, 1991b, 1992) . Quantitative analysis using the LIGAND program (Munson and Rodbard, 1980) A complete set of competition curves in the myometrium from pregnant women is shown in Fig. 1 . Tables 1 and 2 (Maggi et ah, 1988b (Maggi et ah, , 1990 (Maggi et ah, , 1991a (Maggi et ah, , 1992 Figure 3a shows the result of a typical doseresponse experiment. (Manning et ah, 1973) and human (Maggi et ah, 1989) V2 vasopressin receptors, but shows low Table 3. affinity for the V2 vasopressin receptors present in porcine renal medulla (Maggi et ah, 1986 (Maggi et ah, , 1988a . In addition, OTA is a selective antagonist for the rat (Elands et ah, 1988) and rabbit (Maggi et ah, 1991a) oxytocin receptor, but the same com¬ pound is less selective in humans (Maggi et ah, 1990 radioligand binding study (Pettibone et ah, 1992) (Akerlund, 1987) , clinical studies indicate that dETVT is effec¬ tive in inhibiting uterine activity in patients with uncompli¬ cated preterm labour (Akerlund et ah, 1987; Andersen et ah, 1987; Akerlund, 1991 (Maggi et ah, 1990 (Maggi et ah, , 1992 
